Brinzolamide
Lowering intraocular pressure in open-angle glaucoma and ocular hypertension
- CAS No.
- 138890-62-7
- Indication Class
- Ophthalmology
- Patent Expiry
- Off-patent · 2012
- Therapeutic Area
- Ophthalmology
- Target / Mechanism
- CA2
- Labeled Purity
- 98%+
- Registration Readiness
- GMP/DMF
- Commercialization Tier
- API (Commercialized)
- Linked Intermediates
- 2 key intermediates available
- Patent Scope
- Compound patent long expired; mature multi-source generic supply
Key Intermediates for This API
Order: listed intermediates that accept enquiries first; fragments shared across several APIs rank higher| Intermediate | CAS | Shared | Action |
|---|---|---|---|
| (S)-3,4-Dihydro-4-hydroxy-2-(3-methoxypropyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide | 154127-42-1 | — | |
| (S)-3,4-dihydro-6-chloro-4-hydroxy-2H-thieno[3,2-e]-1,2-thiazine-1,1-dioxide | 160982-16-1 | — |
Listing Logic · Why It's Worth Listing
Glaucoma requires lifelong therapy, sustaining steady demand for ophthalmic API; frequently combined with beta-blockers, enabling fixed-dose combination registration.
Ophthalmology · Marketed; available for immediate sourcing
GMP/DMF-ready; supports regulatory filing and audit in target markets
2 key intermediates available; scale-up and cost control manageable
Product Description
Brinzolamide is a medication used in the treatment of glaucoma and ocular hypertension. As a carbonic anhydrase inhibitor, it primarily works by reducing the production of intraocular fluid (aqueous humor), thereby lowering intraocular pressure and helping to prevent vision loss associated with glaucoma.
Supply source: Unibest · Brinzolamide, sourced, vetted and delivered by Unibest. Therapeutic area, indication and listing rationale are qualitative summaries based on public drug knowledge for business reference; actual registration availability and quality specifications are subject to DMF/GMP documentation and the technical agreement confirmed at order.